Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
InspireMD Inc (NSPR)
:NSPR
Holding NSPR?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.16Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: 8.94%
|Next Earnings Date:Aug 06, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and promising prospects for U.S. market entry, supported by a robust pipeline and strategic initiatives. However, challenges included decreased gross profit, increased operating expenses, and a higher net loss, indicating mixed financial performance.Company Guidance
During the InspireMD Q3 2024 earnings call, CEO Marvin Slosman reported significant growth, with CGuard revenue reaching $1.81 million, a 16.3% increase compared to the previous year, and sales of over 3,100 implants, marking a 14% rise. The company's stent technology now holds a double-digit market share in 30 countries, with more than 60,000 implants sold to date. The anticipated U.S. approval of CGuard Prime in the first half of 2025 could potentially translate international sales into over $14 million in U.S. revenue. The company has submitted a PMA to the FDA and expects a decision by early 2025. Financially, InspireMD saw an increase in operating expenses to $8.9 million, a 46.1% rise over the prior year, and reported a net loss of $7.9 million for the quarter. Cash, cash equivalents, and marketable securities stood at $40.4 million as of September 30, 2024.Strong Revenue Growth
Total CGuard revenue of $1.81 million, representing growth of more than 16% over the third quarter of last year. Sales of over 3,100 CGuard implants during the quarter, representing growth of nearly 14% over the same period last year.
U.S. Market Entry Prospects
Submission of PMA to the FDA for CGuard Prime, with a decision anticipated in early 2025. Potential U.S. market launch could generate significant revenue growth.
Pipeline Development and Strategic Initiatives
Approval of investigational device exemption by the FDA for CGuardians 2 pivotal study. Strategic agreement with the Jacobs Institute for an early feasibility study of CGuard Prime.
Financial Position
Cash, cash equivalents, and marketable securities were $40.4 million as of September 30, 2024, compared to $39 million as of December 31, 2023.
New Headquarters Facility
Seamless transition to new headquarters in Miami, Florida to support anticipated U.S. launch and commercialization.
---
NSPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NSPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $2.46 | $2.38 | -3.25% |
| Aug 06, 2024 | $2.96 | $2.98 | +0.68% |
| May 14, 2024 | $2.40 | $2.38 | -0.83% |
| Mar 06, 2024 | $2.63 | $2.53 | -3.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does InspireMD Inc (NSPR) report earnings?
InspireMD Inc (NSPR) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is InspireMD Inc (NSPR) earnings time?
InspireMD Inc (NSPR) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NSPR EPS forecast?
NSPR EPS forecast for the fiscal quarter 2024 (Q4) is -0.2.
---